Clinical, Protocol and Data Management

CPDM项目总结 丹·L邓肯综合肿瘤中心的临床方案和数据管理组件 (DLDCCC)包括临床试验支持股(CTSU)和数据审查和安全监测 委员会。CTSU为行为提供中央管理、研究支持和监督职能 参与DLDCCC的所有非卧床护理中心和医院的癌症相关临床试验。CTSU DLDCCC的所有从事临床研究的成员都可以获得服务。的主要职能 CTSU将提供： 1.协助与临床研究和试验有关的监管和行政事务，包括IRB 合规和批准、持续的修订和续订、外部机构合规(如 FDA)，以及管理文件的维护， 2.临床试验信息学专门知识，特别是维持与癌症有关的临床电子数据库 协议、患者登记和临床数据，以及对应计项目的监测和报告， 3.质量保证/质量控制审核和人员培训，以确保研究团队得到培训 在临床研究的最佳实践中，以及 4.科研护理/临床试验管理。在最近一年1/01/2018-12/31/2018，CTSU 支持了224项干预试验，包括54项由调查员发起的研究，其中30项研究是在 IND和3在一个IDE下。 数据审查和安全监测委员会与临床试验的操作方面是分开的 由CTSU管理，其职能是确保参与者的安全、数据的有效性和适当的 在发现不适当风险的情况下终止研究，或试验似乎不能 进行得很成功。DLDCCC患者安全官员确保癌症中心的所有数据监测 根据批准的监测计划进行试验。 CPDM还监测应计收入，以确保妇女、少数群体、儿童、 以及临床研究中的老年人。

CPDM PROJECT SUMMARY The Clinical Protocol and Data Management component of the Dan L Duncan Comprehensive Cancer Center (DLDCCC) includes the Clinical Trials Support Unit (CTSU) and the Data Review and Safety Monitoring Committees. The CTSU provides central management, research support, and oversight functions for the conduct of cancer-related clinical trials at all ambulatory care centers and hospitals that are part of the DLDCCC. CTSU services are available to all members of the DLDCCC engaged in clinical research. The major functions of the CTSU are to provide: 1. Assistance with regulatory and administrative matters relating to clinical research and trials, including IRB compliance and approval, ongoing amendments and renewal, external agency compliance (such as the FDA), and maintenance of regulatory files, 2. Clinical trials informatics expertise, in particular maintaining an electronic database of cancer-related clinical protocols, patient registry and clinical data, and monitoring and reporting on accrual, 3. Quality Assurance/Quality Control auditing and personnel training to ensure that the research team is trained in best practices in clinical research, and 4. Research nursing/clinical trials management. In the most recent year 01/01/2018–12/31/2018, the CTSU supported 224 interventional trials including 54 investigator-initiated studies, 30 of which are conducted under IND and 3 under an IDE. The Data Review and Safety Monitoring Committees are separate from the operational aspect of clinical trials managed by the CTSU and function to ensure the safety of participants, the validity of data, and the appropriate termination of studies in the event that undue risks have been uncovered, or it appears that trials cannot be conducted successfully. The DLDCCC patient safety officer ensures that all data monitoring for Cancer Center trials is conducted in accordance with the approved monitoring plan. The CPDM also monitors accrual to ensure there is appropriate representation of women, minorities, children, and older adults in clinical research.